Acad Radiol

1. ZHANG HP, Fu F, Fan XQ, Li ZY, et al
   Application Study of Clinical Features Combined With Ultrasound-based Radiomics Nomogram For Grading Diagnosis of Bladder Urothelial Carcinoma.
   Acad Radiol. 2026;33:5208-5217.
   

   >> Share

   
   

   
   Actas Urol Esp (Engl Ed)

2. OZGUR G, Genc YE, Ozdemiroglu C, Bektas BM, et al
   Risk factors for obturator nerve reflex during bipolar transurethral resection of lateral bladder wall tumors.
   Actas Urol Esp (Engl Ed). 2026;50:502007.
   

   >> Share

   
   

   
   Am J Surg Pathol

3. CHENG L, van Leenders GJLH
   International Society of Urological Pathology (ISUP) Multidisciplinary Expert Consultation on Treatment Effects in Prostate and Bladder Cancer: Toward Standardized Pathologic Evaluation in the Era of Precision Medicine.
   Am J Surg Pathol. 2026 Nov 2. doi: 10.1097/PAS.0000000000002646.
   

   >> Share

   
   

   
   Aust J Gen Pract

4. LAWRENTSCHUK N, Carll J, Li P, Henderson K, et al
   Managing complications of ileal conduits in primary care.
   Aust J Gen Pract. 2026;55:774-778.
   

   >> Share

   
   

   
   Biochim Biophys Acta Mol Basis Dis

5. LI K, Tan YK, Li ZB, Xiang R, et al
   JQ1 targeting BRD4 enhances cisplatin-induced pyroptosis via LDHA-mediated ROS release to potentially overcome chemoresistance in bladder cancer.
   Biochim Biophys Acta Mol Basis Dis. 2026 Nov 5:168510.
   

   >> Share

   
   

   
   bioRxiv

6. ATHANS S, Young M, Yu H, Doshi B, et al
   Tumor SETDB1 expression predicts worse overall survival for bladder cancer patients.
   bioRxiv [Preprint]. 2026 Oct 27:2026.10.23.761403.
   

   >> Share

   
   

   
   BJU Int

7. LU H, Zhang Y, Zhao Y, Zhang Y, et al
   Global trends in urological cancers: an analysis of the global burden of disease study 2023.
   BJU Int. 2026;138:1034-1042.
   

   >> Share

   
   
8. SIMARD F, Lacombe MM, Simonyan D, Garneau CA, et al
   Beyond the label 'high-grade': histological heterogeneity as a prognostic marker in Ta non-muscle-invasive bladder cancer.
   BJU Int. 2026 Nov 2. doi: 10.1111/bju.70522.
   

   >> Share

   
   

   
   BMC Cancer

9. ZHENG W, Yao C, Wang Z, Zhang C, et al
   The predictive value of PD-1 for the response to immune checkpoint inhibitor therapy in patients with bladder cancer without lymph node metastasis and its association with survival outcomes.
   BMC Cancer. 2026;26:1348.
   

   >> Share

   
   

   
   BMC Urol

10. Y PATEL M, Wang X, Castelino R, Milloy N, et al
    Evolution of treatment distribution and patient characteristics of muscle invasive bladder cancer patients: results from two multi-national real-world surveys.
    BMC Urol. 2026;26:274.
    

    >> Share

    
    
11. LI G, Tan C, Wei J, Chen S, et al
    Prognostic value of the inflammatory prognostic index for postoperative recurrence in non-muscle-invasive bladder cancer.
    BMC Urol. 2026;26:275.
    

    >> Share

    
    
12. TOBE T, Miyata Y, Nakamura Y, Hara T, et al
    Exploring vertical genomic heterogeneity and chemotherapy response using targeted genomic sequencing in muscle-invasive bladder cancer.
    BMC Urol. 2026;26:276.
    

    >> Share

    
    
13. TUNCEKIN A, Aktas Y, Turk H, Tongal A, et al
    Diagnostic stage discordance and survival in T2 bladder cancer: rethinking the clinical behavior of progressive disease.
    BMC Urol. 2026;26:278.
    

    >> Share

    
    

    
    Cancer

14. ATIQ SO, Anker JF, Miller EJ, Karol AB, et al
    The evolving role of perioperative systemic therapy in bladder cancer.
    Cancer. 2026;132:e70629.
    

    >> Share

    
    

    
    Cancer Cytopathol

15. WOJCIK EM
    Beyond morphology: Toward integrated risk assessment in urinary cytology.
    Cancer Cytopathol. 2026;134:e70164.
    

    >> Share

    
    

    
    Cancer Diagn Progn

16. ENDERLIN D, Gloor M, Bieri U, Mazumdar A, et al
    Prognostic Impact of Nectin4 and IRF6 Expression in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Cancer Diagn Progn. 2026;6:947-960.
    

    >> Share

    
    

    
    Cancer Invest

17. WANG Y, Wu X, Shu C, Bao T, et al
    SLC9A3R1 Promotes Bladder Cancer Progression Through Regulation of Malignant Phenotypes: Integrated Bioinformatics Analysis and Experimental Validation.
    Cancer Invest. 2026 Nov 1:1-16. doi: 10.1080/07357907.2026.2757870.
    

    >> Share

    
    

    
    Cancer Manag Res

18. HUANG LH, Tung MC, Weng WC, Hsu CY, et al
    Neoadjuvant Nivolumab-Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study.
    Cancer Manag Res. 2026;18:642002.
    

    >> Share

    
    

    
    Cell Death Dis

19. JACOBI JJ, Xu D, Wieczorek K, Wang L, et al
    Single-cell profiling uncovers a rare mesenchymal-like urothelial state associated with sarcomatoid bladder cancer.
    Cell Death Dis. 2026;17:927.
    

    >> Share

    
    

    
    Cell Signal

20. HUANG S, Li Y, Shi Y, Zhang F, et al
    piR-34379 inhibits bladder cancer progression and reverses cisplatin resistance by downregulating ACAT2-mediated PKM2 lactylation.
    Cell Signal. 2026 Nov 3:112978. doi: 10.1016/j.cellsig.2026.112978.
    

    >> Share

    
    

    
    Clin Cancer Res

21. ZHONG Y, Li Y, Wang Q, Cai J, et al
    Integrated multi-omics reveals longitudinal metabolic dynamics and reprogramming in bladder cancer.
    Clin Cancer Res. 2026 Nov 6. doi: 10.1158/1078-0432.CCR-26-1201.
    

    >> Share

    
    

    
    Curr Gene Ther

22. GUAN H, Liu X, Hong T, Li H, et al
    Integrative Multi-Omics Analysis with Interpretable Machine Learning Prioritizes Candidate Biomarkers for Bladder Cancer.
    Curr Gene Ther. 2026 Oct 27. doi: 10.2174/0115665232538656261006070001.
    

    >> Share

    
    

    
    Eur Urol Focus

23. SIVA J, McKenney JK, Guzman T, Diaz GM, et al
    Clinical Outcomes and Malignant Potential of Urothelial Atypia Without Previous Bladder Cancer.
    Eur Urol Focus. 2026 Nov 4:S2405-4569(26)00261-0. doi: 10.1016/j.euf.2026.
    

    >> Share

    
    

    
    Eur Urol Oncol

24. LOTAN Y, Korman H, Gadzinski A, Cohen J, et al
    Postinduction Urine Tumor DNA Is Predictive for Response to Maintenance Intravesical Therapy in Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2026 Oct 31:S2588-9311(26)00286.
    

    >> Share

    
    

    
    Eur Urol Open Sci

25. NIELSEN NK, Jensen JB
    Reply to Xin Li and Yapeng Xing's Letter to the Editor re: Nielsen N.K, Hjort P.B, Hansen E.B, et al. Substaging and stratified treatment of T1 bladder cancer - a nationwide register-based study. Eur Urol Open Sci 2026;90:92-100.
    Eur Urol Open Sci. 2026;93:65-66.
    

    >> Share

    
    

    
    Front Cardiovasc Med

26. MA W, Liu Y, Tang L, Ouyang S, et al
    Serial urinary NGAL and CK20 for dynamic cardiovascular risk stratification in non-muscle-invasive bladder cancer: a retrospective clinical cohort study.
    Front Cardiovasc Med. 2026;13:1949457.
    

    >> Share

    
    

    
    Front Cell Dev Biol

27. LI D, Sun X, Yu T
    From epidemiology to molecular pathology: current research status and future prospects on the role of toxic metal exposure in the development and progression of bladder cancer.
    Front Cell Dev Biol. 2026;14:1930640.
    

    >> Share

    
    

    
    Front Immunol

28. LIU J, Guo Z, Guo J, Xing S, et al
    Evidence gaps and route-dependent development requirements for CAR cellular therapy in urothelial carcinoma: a systematic evidence map and public-data analysis.
    Front Immunol. 2026;17:1941701.
    

    >> Share

    
    
29. ZHANG C, Zhang Z, Bi J
    Therapy-induced methionine competition in bladder cancer: MAT2A-SAM axis remodeling as a metabolic immune checkpoint.
    Front Immunol. 2026;17:1965813.
    

    >> Share

    
    
30. CHEN C, Xie B, Chen C, Gu P, et al
    Defining safe bladder preservation in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: beyond complete response.
    Front Immunol. 2026;17:1983996.
    

    >> Share

    
    
31. SONG DM, Lu H, Shu YC, Xu JJ, et al
    Overexpression of TUBA1A suppresses bladder cancer progression with potential modulation of autophagic activity and macrophage polarization.
    Front Immunol. 2026;17:1921855.
    

    >> Share

    
    

    
    Front Nutr

32. QIN B, Liang H, Kuang T, Wei C, et al
    Anti-bladder cancer effects of nuciferine, a bioactive compound extracted from Nelumbo nucifera leaves.
    Front Nutr. 2026;13:1881388.
    

    >> Share

    
    

    
    Front Oncol

33. NAIM N, Saad A, Mohamad N, Kattan J, et al
    Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making.
    Front Oncol. 2026;16:1933232.
    

    >> Share

    
    

    
    Funct Integr Genomics

34. LIU Y, Bian Z, Hu J, Xie Y, et al
    Integrative multi-omics analysis reveals a GALNT6/Smad2/CDC7 axis promoting cisplatin resistance through enhanced DNA damage repair in bladder cancer.
    Funct Integr Genomics. 2026;26:315.
    

    >> Share

    
    

    
    Hinyokika Kiyo

35. HAYASHI Y, Iida K, Narita K, Itami Y, et al
    [A CASE OF POLYMYALGIA RHEUMATICA (PMR)-LIKE irAE DEVELOPING DURING NIVOLUMAB ADMINISTRATION AFTER SURGERY FOR MUSCLE-INVASIVE BLADDER CANCER : A CASE REPORT].
    Hinyokika Kiyo. 2026;72:319-323.
    

    >> Share

    
    
36. ABE S, Tsutsumi N, Hoshiyama A, Kamiyama Y, et al
    [A CASE OF BCG-ASSOCIATED INTERSTITIAL PNEUMONIA WITH Mycobacterium bovis BACTEREMIA SUCCESSFULLY TREATED WITH CORTICOSTEROIDS ALONE].
    Hinyokika Kiyo. 2026;72:325-329.
    

    >> Share

    
    

    
    Histopathology

37. NGUYEN JK, Toscano MP, Li J, Williamson SR, et al
    Hybrid grading systems improve progression risk stratification in non-invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression.
    Histopathology. 2026;89:1064-1082.
    

    >> Share

    
    

    
    Int J Urol

38. SHAHZAD MH
    Beyond Association: Clarifying the Biological and Clinical Value of Urinary EphA2 in Bladder Cancer.
    Int J Urol. 2026;33:e70697.
    

    >> Share

    
    
39. MIYAKE M
    Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis.
    Int J Urol. 2026;33:e70699.
    

    >> Share

    
    

    
    Investig Clin Urol

40. MAENG S, Kim MJ, Kim M, Tae JH, et al
    Ultrasound-triggered release of gemcitabine-loaded liposomes enhances intravesical therapy for bladder cancer.
    Investig Clin Urol. 2026;67:587-597.
    

    >> Share

    
    
41. NOMURA N, Sekino Y, Shigematsu Y, Kobayashi G, et al
    KIF23 is associated with a poor prognosis, basal subtypes and immunotherapy response in urothelial carcinoma.
    Investig Clin Urol. 2026;67:530-542.
    

    >> Share

    
    

    
    iScience

42. ZHU S, Kohler L, Ergun B, Meierhofer D, et al
    An MMP-14/STAT3 feedback loop upregulates PD-L1 to drive immunosuppression and tumorigenesis in bladder cancer.
    iScience. 2026;29:118071.
    

    >> Share

    
    

    
    J Biophotonics

43. HOU L, Xiao Y, Xiao K, Tao X, et al
    Detection of Stage-Dependent Collagen Remodeling at the Bladder Cancer Invasive Front by Label-Free Multiphoton Imaging.
    J Biophotonics. 2026;19:e70387.
    

    >> Share

    
    

    
    J Comp Eff Res

44. GUERRERO-RAMOS F, Fernandez Gomez JM, Aparicio TF, Lopez-Beltran A, et al
    Evaluation of large language models for guideline-based clinical questions in muscle-invasive and non-muscle-invasive bladder cancer and upper tract urothelial carcinoma: a multidisciplinary Delphi study.
    J Comp Eff Res. 2026 Nov 4:e260079. doi: 10.57264/cer-2026-0079.
    

    >> Share

    
    

    
    J Exp Clin Cancer Res

45. MAO W, Huang X, Wang L, Zhang Z, et al
    Retraction Note: Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression.
    J Exp Clin Cancer Res. 2026;45:229.
    

    >> Share

    
    

    
    J Helminthol

46. UNAL B, Imanli G, Ilki FY, Bedir S, et al
    Short communication: Urinary schistosomiasis mimicking a bladder tumour in a Somali student diagnosed in Turkiye.
    J Helminthol. 2026;100:e156.
    

    >> Share

    
    

    
    J Hosp Med

47. ROUDSARI H, Dhaliwal G, Jagannath AD, Baik AH, et al
    Old disease, new twist.
    J Hosp Med. 2026;21:1305-1309.
    

    >> Share

    
    

    
    J Pharm Anal

48. ZHANG J, Zhou H, Li J, Liu T, et al
    Exploring the role of RPS2 in muscle-invasive bladder cancer progression and resistance: A nanovesicle-based therapeutic approach.
    J Pharm Anal. 2026;16:101628.
    

    >> Share

    
    

    
    JCO Precis Oncol

49. HUANG S, Xue Z, Kang N, Ma B, et al
    Postresection Urinary Tumor DNA Refines Residual Disease Assessment and Recurrence Risk Stratification in Non-Muscle-Invasive Bladder Cancer.
    JCO Precis Oncol. 2026;10:e2600676.
    

    >> Share

    
    

    
    Lifetime Data Anal

50. CHEE CS, Ha ID, Lee Y, Lee H, et al
    Nonparametric maximum likelihood estimation for competing risks frailty models.
    Lifetime Data Anal. 2026;32:57.
    

    >> Share

    
    

    
    Mol Pharm

51. WOOD JL, Lum B, Ghosh S, Staudacher AH, et al
    Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer.
    Mol Pharm. 2026;23:5879-5890.
    

    >> Share

    
    

    
    Oncol Res

52. DONG X, Zhang J, Liu M, Sun R, et al
    Advances in Novel Protein Acylation in Urothelial Carcinoma: Research Progress and Biomarker Potential.
    Oncol Res. 2026;34:13.
    

    >> Share

    
    

    
    Open Life Sci

53. ZHANG G, Mu J, Shi X, Bao Z, et al
    Preliminary development and internal evaluation of a plasma SOX1 methylation-based model bladder cancer detection.
    Open Life Sci. 2026;21:20251396.
    

    >> Share

    
    

    
    Urology

54. NGUYEN SL, Baer BR, Bruno N, Raman JD, et al
    Clinical Implications of Discordant Urinalysis and Urine Culture Findings Before Urologic Surgery.
    Urology. 2026;216:10-16.
    

    >> Share

    
    

    
    World J Urol

55. CONTIERI R, de Angelis M, Scilipoti P, Pellegrino F, et al
    When, where, and in whom does recurrence occur after radical cystectomy for pathologically confirmed non-muscle-invasive bladder cancer? Implications for risk-adapted surveillance.
    World J Urol. 2026;44:780.
    

    >> Share

    
    
56. MIYAJIMA K, Miszczyk M, Rabil MJ, Lubbersmeyer F, et al
    Intravesical BCG-induced granulomatous prostatitis mimicking prostate cancer in patients with non-muscle invasive bladder cancer: a systematic review.
    World J Urol. 2026;44:787.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share